Published in Exp Eye Res on September 15, 2005
Bovine and porcine transscleral solute transport: influence of lipophilicity and the Choroid-Bruch's layer. Invest Ophthalmol Vis Sci (2006) 1.18
Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications. Invest Ophthalmol Vis Sci (2010) 1.17
Treatment of sheep steroid-induced ocular hypertension with a glucocorticoid-inducible MMP1 gene therapy virus. Invest Ophthalmol Vis Sci (2010) 1.11
Modeling of corneal and retinal pharmacokinetics after periocular drug administration. Invest Ophthalmol Vis Sci (2008) 0.98
Examination of penetration routes and distribution of ionic permeants during and after transscleral iontophoresis with magnetic resonance imaging. Int J Pharm (2006) 0.97
Drug and gene delivery to the back of the eye: from bench to bedside. Invest Ophthalmol Vis Sci (2014) 0.93
Suprachoroidal delivery in a rabbit ex vivo eye model: influence of drug properties, regional differences in delivery, and comparison with intravitreal and intracameral routes. Mol Vis (2013) 0.91
Ocular delivery of macromolecules. J Control Release (2014) 0.91
Transscleral iontophoretic and intravitreal delivery of a macromolecule: study of ocular distribution in vivo and postmortem with MRI. Exp Eye Res (2008) 0.89
Comparison of suprachoroidal drug delivery with subconjunctival and intravitreal routes using noninvasive fluorophotometry. PLoS One (2012) 0.88
Transscleral diffusion of ethacrynic acid and sodium fluorescein. Mol Vis (2007) 0.88
Drug delivery to posterior intraocular tissues: third Annual ARVO/Pfizer Ophthalmics Research Institute Conference. Invest Ophthalmol Vis Sci (2008) 0.86
MRI in ocular drug delivery. NMR Biomed (2008) 0.84
Influence of choroidal neovascularization and biodegradable polymeric particle size on transscleral sustained delivery of triamcinolone acetonide. Int J Pharm (2012) 0.81
Examination of barriers and barrier alteration in transscleral iontophoresis. J Pharm Sci (2008) 0.81
In vivo ocular fluorophotometry: delivery of fluoresceinated dextrans via transscleral diffusion in rabbits. Invest Ophthalmol Vis Sci (2011) 0.81
Passive and oxymetazoline-enhanced delivery with a lens device: pharmacokinetics and efficacy studies with rabbits. J Ocul Pharmacol Ther (2008) 0.79
Transscleral sustained vasohibin-1 delivery by a novel device suppressed experimentally-induced choroidal neovascularization. PLoS One (2013) 0.77
Inhibition of corneal neovascularization with the combination of bevacizumab and plasmid pigment epithelium-derived factor-synthetic amphiphile INTeraction-18 (p-PEDF-SAINT-18) vector in a rat corneal experimental angiogenesis model. Int J Mol Sci (2013) 0.76
Evaluation of the intravenous and topical routes for ocular delivery of hesperidin and hesperetin. J Ocul Pharmacol Ther (2012) 0.76
Episcleral clearance of sodium fluorescein from a bioerodible sub-tenon's implant in the rat. Exp Eye Res (2010) 0.75
Drug delivery to the eye through systematic circulation following subconjonctival injection. Graefes Arch Clin Exp Ophthalmol (2006) 0.75
Applications of polymers in intraocular drug delivery systems. Oman J Ophthalmol (2017) 0.75
MRI study of subconjunctival and intravitreal injections. J Pharm Sci (2012) 0.75
Delivery of intraocular triamcinolone acetonide in the treatment of macular edema. Pharmaceutics (2012) 0.75
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res (2008) 5.34
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation (2008) 3.63
Large-scale proteomics and phosphoproteomics of urinary exosomes. J Am Soc Nephrol (2008) 3.22
Macrophage depletion diminishes lesion size and severity in experimental choroidal neovascularization. Invest Ophthalmol Vis Sci (2003) 3.04
The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res (2009) 2.25
Selective loss of imprinting in the placenta following preimplantation development in culture. Development (2004) 2.23
A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum (2005) 2.20
Angiophagy prevents early embolus washout but recanalizes microvessels through embolus extravasation. Sci Transl Med (2014) 2.11
Procedural volume and structure of interventional pulmonary fellowships: a survey of fellows and fellowship program directors. Chest (2013) 2.06
The involvement of sequence variation and expression of CX3CR1 in the pathogenesis of age-related macular degeneration. FASEB J (2004) 2.04
Stability of alemtuzumab solutions at room temperature. Am J Health Syst Pharm (2013) 2.03
The Advanced Glaucoma Intervention Study (AGIS): 13. Comparison of treatment outcomes within race: 10-year results. Ophthalmology (2004) 2.01
Serum inflammatory markers in diabetic retinopathy. Invest Ophthalmol Vis Sci (2005) 1.92
Analysis of binding at a single spatially localized cluster of binding sites by fluorescence recovery after photobleaching. Biophys J (2006) 1.78
Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. J Immunother (2004) 1.77
Prospects for urinary proteomics: exosomes as a source of urinary biomarkers. Nephrology (Carlton) (2005) 1.77
Reprogramming of primordial germ cells begins before migration into the genital ridge, making these cells inadequate donors for reproductive cloning. Proc Natl Acad Sci U S A (2003) 1.73
Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res (2006) 1.67
Neural basis of irony comprehension in children with autism: the role of prosody and context. Brain (2006) 1.63
Quantitative assessment of angiogenic responses by the directed in vivo angiogenesis assay. Am J Pathol (2003) 1.61
Reading affect in the face and voice: neural correlates of interpreting communicative intent in children and adolescents with autism spectrum disorders. Arch Gen Psychiatry (2007) 1.60
Monocyte activation in patients with age-related macular degeneration: a biomarker of risk for choroidal neovascularization? Arch Ophthalmol (2004) 1.57
A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies. Blood (2013) 1.56
Prevalence of posterior subcapsular cataracts in volunteer cytapheresis donors. Transfusion (2010) 1.51
Developmental changes in the neural basis of interpreting communicative intent. Soc Cogn Affect Neurosci (2006) 1.47
Isolation and purification of exosomes in urine. Methods Mol Biol (2010) 1.44
AAPS-FDA workshop white paper: microdialysis principles, application and regulatory perspectives. Pharm Res (2007) 1.35
Bone marrow-derived progenitor cells contribute to experimental choroidal neovascularization. Invest Ophthalmol Vis Sci (2003) 1.32
The long-term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow-up study. Ophthalmology (2003) 1.30
Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem (2006) 1.29
Genome-wide interrogation identifies YAP1 variants associated with survival of small-cell lung cancer patients. Cancer Res (2010) 1.25
The remediation of heavy metals contaminated sediment. J Hazard Mater (2008) 1.25
Age as an independent risk factor for severity of experimental choroidal neovascularization. Invest Ophthalmol Vis Sci (2002) 1.23
Implementation of a reference-scaled average bioequivalence approach for highly variable generic drug products by the US Food and Drug Administration. AAPS J (2012) 1.22
Transport barriers in transscleral drug delivery for retinal diseases. Ophthalmic Res (2007) 1.17
Controlled drug release from an ocular implant: an evaluation using dynamic three-dimensional magnetic resonance imaging. Invest Ophthalmol Vis Sci (2004) 1.17
Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications. Invest Ophthalmol Vis Sci (2010) 1.17
FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye. Mol Vis (2009) 1.16
Gonadotropin-inhibitory hormone neurons interact directly with gonadotropin-releasing hormone-I and -II neurons in European starling brain. Endocrinology (2007) 1.16
Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate. Cancer Res (2002) 1.15
SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies. Clin Cancer Res (2011) 1.14
DNA Methylation in Whole Blood: Uses and Challenges. Curr Environ Health Rep (2015) 1.14
Vitreous VEGF clearance is increased after vitrectomy. Invest Ophthalmol Vis Sci (2009) 1.13
Antibody-maytansinoid conjugates designed to bypass multidrug resistance. Cancer Res (2010) 1.11
Regulation of estrogen receptors and MMP-2 expression by estrogens in human retinal pigment epithelium. Invest Ophthalmol Vis Sci (2003) 1.10
Central visual function and the NEI-VFQ-25 near and distance activities subscale scores in people with type 1 and 2 diabetes. Am J Ophthalmol (2005) 1.10
Nonlethal oxidant injury to human retinal pigment epithelium cells causes cell membrane blebbing but decreased MMP-2 activity. Invest Ophthalmol Vis Sci (2005) 1.08
Safety and pharmacokinetics of a preservative-free triamcinolone acetonide formulation for intravitreal administration. Retina (2006) 1.08
Genetic variation in an miRNA-1827 binding site in MYCL1 alters susceptibility to small-cell lung cancer. Cancer Res (2011) 1.08
Transscleral-RPE permeability of PEDF and ovalbumin proteins: implications for subconjunctival protein delivery. Invest Ophthalmol Vis Sci (2005) 1.07
Fluorescein angiographic findings in primary intraocular lymphoma. Retina (2002) 1.05
Quantitative no-net-flux microdialysis permits detection of increases and decreases in dopamine uptake in mouse nucleus accumbens. J Neurosci Methods (2006) 1.05
The role of predictive biopharmaceutical modeling and simulation in drug development and regulatory evaluation. Int J Pharm (2011) 1.04
Quantitative enumeration of vascular smooth muscle cells and endothelial cells derived from bone marrow precursors in experimental choroidal neovascularization. Exp Eye Res (2005) 1.04
Mapping of the neonatal Fc receptor in the rodent eye. Invest Ophthalmol Vis Sci (2008) 1.04
Intraocular pharmacokinetics of ranibizumab in vitrectomized versus nonvitrectomized eyes. Invest Ophthalmol Vis Sci (2014) 1.02
Assessment of subconjunctival and intrascleral drug delivery to the posterior segment using dynamic contrast-enhanced magnetic resonance imaging. Invest Ophthalmol Vis Sci (2007) 1.02
Late outgrowth endothelial progenitor cells in patients with age-related macular degeneration. Invest Ophthalmol Vis Sci (2008) 1.02
Survival of retinal pigment epithelium after exposure to prolonged oxidative injury: a detailed gene expression and cellular analysis. Invest Ophthalmol Vis Sci (2004) 1.01
AAPS-FDA Workshop White Paper: microdialysis principles, application, and regulatory perspectives. J Clin Pharmacol (2007) 1.01
Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage. Bioconjug Chem (2011) 1.01
Zidovudine concentration in brain extracellular fluid measured by microdialysis: steady-state and transient results in rhesus monkey. J Pharmacol Exp Ther (2002) 0.99
Assessment of XPD Lys751Gln and XRCC1 T-77C polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy. Lung Cancer (2010) 0.99
Angiogenesis inhibition and choroidal neovascularization suppression by sustained delivery of an integrin antagonist, EMD478761. Invest Ophthalmol Vis Sci (2007) 0.99
A novel bioerodible deep scleral lamellar cyclosporine implant for uveitis. Invest Ophthalmol Vis Sci (2006) 0.98
A functional -77T>C polymorphism in XRCC1 is associated with risk of breast cancer. Breast Cancer Res Treat (2010) 0.98
Characterization of functional excision repair cross-complementation group 1 variants and their association with lung cancer risk and prognosis. Clin Cancer Res (2008) 0.98
Tarsal-conjunctival disease associated with Wegener's granulomatosis. Ophthalmology (2003) 0.98
Attachment site recognition and regulation of directionality by the serine integrases. Nucleic Acids Res (2013) 0.97
Functional and structural analysis of the human SLO3 pH- and voltage-gated K+ channel. Proc Natl Acad Sci U S A (2012) 0.96
Investigating the movement of intravitreal human serum albumin nanoparticles in the vitreous and retina. Pharm Res (2008) 0.95
Retracted Matrix metalloproteinase 9 expression and prognosis in colorectal cancer: a meta-analysis. Tumour Biol (2012) 0.95
Characterization of probe and tissue factors that influence interpretation of quantitative microdialysis experiments for dopamine. J Neurosci Methods (2003) 0.95
An apolipoprotein E variant may protect against age-related macular degeneration through cytokine regulation. Environ Mol Mutagen (2006) 0.94
Improving the reporting of adverse drug reactions in the hospital setting. Postgrad Med (2010) 0.93
Review of microdialysis in brain tumors, from concept to application: first annual Carolyn Frye-Halloran symposium. Neuro Oncol (2004) 0.92
The movement of self-assembled amphiphilic polymeric nanoparticles in the vitreous and retina after intravitreal injection. Biomaterials (2012) 0.92
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves the survival of gastric cancer patients with ovarian metastasis and peritoneal dissemination. Tumour Biol (2012) 0.92
Developing Bacillus spp. as a cell factory for production of microbial enzymes and industrially important biochemicals in the context of systems and synthetic biology. Appl Microbiol Biotechnol (2013) 0.91
Drug elimination kinetics following subconjunctival injection using dynamic contrast-enhanced magnetic resonance imaging. Pharm Res (2007) 0.91
Evaluation of the age-related eye disease study clinical lens grading system AREDS report No. 31. Ophthalmology (2010) 0.91
Study of ocular transport of drugs released from an intravitreal implant using magnetic resonance imaging. Ann Biomed Eng (2005) 0.90